Nagla A. Karim, Hai Bui, Peterson Pathrose, Sandra Starnes, Ninad Patil, Mahmoud Shehata, Ahmed Mostafa, MB Rao, Ahmad Zarzour and Marshall Anderson

[Clinical Medicine Insights: Oncology] Performance status is the only known clinical predictor of outcome in patients with advanced non-small-cell lung cancer (NSCLC), but pharmacogenomic markers may also correlate with outcome. This study attempts to correlate clinical and pharmacogenomic measures with overall survival.